Prescription abandonment is a significant challenge faced by health systems, reflecting a broader operational issue rather than merely a patient affordability concern. Each unfilled order leads to increased callbacks, additional documentation, and added workflow steps for care teams. Most health systems view abandonment as a warning sign, yet the deeper implication lies in the operational strain it creates. This phenomenon not only represents a cost burden for patients but also contributes to administrative pressure, FTE creep, and workflow friction that ultimately impacts the efficiency of care teams.
Roughly 27% of all prescriptions in the United States go unfilled, with abandonment rates rising to 67% at the pharmacy counter when out-of-pocket costs top $250 (IQVIA, 2025). While headlines focus on the patient struggle, health system leaders know firsthand this is a workflow problem. Each abandoned script becomes another callback, resubmission, or rescript for staff. This workflow gap—measured in diversion of FTE hours, administrative loops, and mounting paperwork—lands squarely on medication-access programs and clinic operators. Prescription abandonment is not just a patient outcome metric. It marks an activation gap that burdens care teams daily and routinely escapes detection as a true system cost.
For operations leaders, abandonment is not an abstraction. Each episode becomes quantifiable work: EMR queues fill with callbacks. Faxed prior authorizations stack up. Provider inboxes overflow with rescript requests. Teams can anticipate workflow spikes the moment new therapies hit.
Abandonment is more prevalent than most realize, particularly when recognized as operational noise. 27% of prescriptions go unfilled, climbing to 34% for Medicaid, 24% for Medicare, and 28% for commercial payers (IQVIA, 2025). At the counter, 67% of patients with more than $250 in out-of-pocket exposure abandon therapy, with specialty drug rates even higher (IQVIA, 2025).
It is tempting to isolate this to financial hardship or patient choice. In reality, each case creates records to pull, calls to return, forms to resubmit. The cumulative operational cost dogs care teams, straining both productivity and morale. Abandonment is not just a trailing indicator: it creates a workflow gap that drives the bulk of real work for access teams.
The real pain is downstream. Health systems run lean. Any uptick in administrative work amplifies stress on already stretched FTEs.
A denied or abandoned prescription triggers a predictable cycle: the medication-access coordinator responds to a pharmacy flag, or fields a patient complaint after a rejected pickup. The coordinator verifies coverage, pursues missing PA, completes manufacturer enrollment, or hunts for a formulary alternative. If this work stalls, the cycle begins anew: more calls, more rescripts, more delays, a wider workflow gap between prescribing and therapy start.
Surveys indicate care teams handle an average of 43 prior authorizations per physician per week (AMA, 2024). Each PA can take 15 minutes or more to complete—retrieval, documentation, submission, and follow-up (AMA, 2024). That accumulation swells quickly across a health system.
Staffing models now accommodate this invisible drain. About 30% of hospitals have expanded FTEs to manage the ballooning load of PA and callbacks (AHA, 2021). Each abandonment event quietly shifts from patient experience to operational cost, absorbed by care teams on the ground.
The prevailing story says abandonment is about affordability. Cost matters—patients drop off when out-of-pocket spend exceeds $250—but operationally, that’s only step one (IQVIA, 2025). From the care team vantage, the main forces are process drag and fragmentation.
The pain points are as much about documentation and missed moments as about price: PA waiting periods, confusion over enrollment steps, misfires in referring patients to programs, and poor pharmacy-to-clinic communication. Delays pile up. Health Affairs documented a median twelve-day treatment delay for cancer patients due to prior authorization alone (Health Affairs, 2020).
Nearly 88% of hospital leaders report administrative tasks are now pulling staff from direct patient care (AHA, 2021). Practices cite two full-time personnel handling PA and pharmacy callbacks on average (MGMA, 2023). These workflow gaps are not cost-of-care line items, but they are palpable and growing pressures.
Executives removed from the clinical coalface often underestimate the scale of the workflow burden. Despite the move to digital records, manual intervention persists. Electronic systems often fragment responsibility, muddying the true ownership of each task.
Ambulatory providers spend about a third of their work time on EHR-related tasks, including order entry, documentation, and PA. Of this, close to two hours per week, per physician, is devoted specifically to PA routines (JAMA Internal Medicine, 2021).
For medication-access directors, workforce models have adapted to these hidden forces. Specialty volumes surge, or payer plans change, and teams add mid-year FTEs just to keep up. Nearly 29% of hospitals reported these adjustments to cope with workflow gaps created by PA and callback loads (AHA, 2021).
Over a decade, the sector poured resources into affordability and access tools. 97% of prescriptions now pass through e-prescribing channels (Surescripts, 2023). ePA technology is standard issue, pushing some approvals to under two minutes (Surescripts, 2023).
Still, these platforms attack individual process segments, not end-to-end workflow. ePA accelerates the PA decision only if entered data is complete and upstream steps are smooth. Most manufacturer or pharmacy partners use out-of-band portals, forcing staff to manage fragmented logins, reconcile statuses manually, and absorb callbacks that should be superfluous.
Teams face not an affordability gap alone, but a workflow gap. One script is routed through three or more platforms: benefits verification, PA, enrollment. With every handoff comes risk—missed signals, repeated documentation, or outright abandonment.
Digital innovation has not lightened the load; it has distributed it. The last-mile execution remains firmly with the care team.
Abandonment, in most cases, is rooted in a workflow gap. The processes for affordability discovery, prior authorization, and enrollment remain separate. When a patient abandons therapy, the real cause often remains unclear. The fallout circles back to the clinic, regardless of whether the breakdown was a missed PA, incomplete paperwork, or an unknown legal hurdle.
Payer restrictions tighten every year. In 2025, nearly half of new branded Medicare Part D claims received an initial denial, and 14% were never approved (IQVIA, 2026). That administrative churn is returned, in almost every case, to care teams who must resolve the workflow gap.
Here is the hidden tax: FTEs are added, patient care time drains into repetitive loops, and staff morale suffers. These operational losses rarely make financial highlights, but for health systems, they are rising year over year.
Abandonment is less a symptom of patient choice or affordability and more a sign that the workflow activation gap has surfaced. Framing abandonment as an activation gap—where fragmented discovery, PA, and enrollment steps never coalesce into a connected, in-EHR flow—reshapes priorities: operational relief is possible only when access teams control the workflow, not just the endpoints.
So long as prescription access relies on disconnected processes, care teams will keep owning all the churn: callbacks, rescripts, repeated documentation, staffing up just to survive. The standard for operational readiness must be this: every activation step—from affordability discovery to PA to final enrollment—should be surfaced, closed, and tracked inside the EHR workflow, connected from prescribing to therapy start. Defining and measuring the activation gap is now an operational imperative for any health system aiming to reclaim care team capacity.
Effort across the industry has been real but fragmented. Medication-access programs map processes, build dashboards, and drill into call volumes and abandonment rates by specialty. Specialty pharmacy teams monitor their highest-risk classes and identify which plans demand the heaviest PA loads. Health-system EMR teams hack together better workflows: embedding links, building templates, staffing for the latest obstacles. The result so far is patchwork fixes atop a broken activation pathway.
Today's competitor categories are disjointed by design. ePA platforms (CoverMyMeds) automate one part of the chain. Hub services (Mercalis, Relay) solve downstream enrollment and follow-up after a script is written. Consumer coupon channels (GoodRx) lower cost at retail checkout but sit outside the clinical flow entirely. Each narrows a slice of the access gap. None connects the journey end to end inside the EHR where daily work actually happens. That is classic workflow fragmentation, and care teams pay for it in callbacks, rescripts, and FTE creep every week.
The most durable new models close the loop differently. They tie affordability discovery, real-time benefit check, electronic PA, guided enrollment, activation confirmation, and patient-level analytics into a single EHR-native path. No third-party pivots, no missed documentation, no handoff risk. co-pay.com builds that layer: every element from discovery to ePA, AI-driven enrollment, and closed-loop activation analytics runs as one workflow inside the EHR. The shift is from compartmentalized tools to a unified workflow surface, so care teams spend time with patients, not with paperwork.
Operational leaders will not escape constraints overnight. Existing vendor contracts, entrenched workflows, and IT silos make change slow. Still, the real shift is becoming unavoidable: as payer rigor mounts and therapy complexity grows, care teams cannot keep paying the hidden tax of fragmented workflows.
The critical next step is to name the activation gap for what it is: the recurring workflow gap that transforms every abandoned prescription into an FTE problem, an invisible drain, and a morale risk. Systems that close this gap—surfacing and closing all activation moments within one EHR-native process—empower care teams to focus on care instead of wrangling paperwork. Operational dividends will come not from another point solution, but from building the workflow teams have needed all along.
Prescription abandonment refers to a written prescription that is never picked up or filled by the patient, often due to reasons like high out-of-pocket costs, prior authorization delays, enrollment issues, or unclear pharmacy communication. It is a key driver of care-team workflow burden, especially in specialty and high-cost therapies (IQVIA, 2025; Surescripts, 2023).
For health systems, every abandoned prescription creates manual work: callbacks from pharmacies, repeated prior authorization submissions, rescript requests to providers, and lost productivity for care teams. This operational burden can require additional FTEs just to manage the increased volume (AHA, 2021; MGMA, 2023).
The cost is measured in diverted staff hours, increased FTE hiring, and lost provider capacity. Practices report at least two full-time staff just for PA and related callbacks, with each PA taking an average of 15+ minutes (MGMA, 2023; AMA, 2024). Hospital leaders report nearly 30% have added FTEs for this workload in the past year (AHA, 2021).
Specialty prescriptions face stricter payer controls and higher PA denial rates. If the initial submission is missing required forms or documentation, or if enrollment in manufacturer programs is incomplete, the staff must repeat the process, triggering a rescript. Delays and denials are routine, and each rescript adds to the workflow burden (IQVIA, 2026; Health Affairs, 2020).
Most callbacks trace back to unresolved prior authorizations, incomplete enrollment, or affordability gaps that block dispensing. The pharmacy contacts the prescribing clinic or medication access team for clarification, leading to repeated documentation, phone calls, or form completion by staff (MGMA, 2023; AMA, 2024).
Physicians and staff spend an average of 13–15 hours per week per physician handling prior authorization-related tasks. This can add up quickly across group practices and health systems, substantially diverting provider time from direct patient care (AMA, 2024; MGMA, 2023).
Yes. Adoption of electronic prior authorization and in-workflow activation solutions has been shown to cut PA decision times to under two minutes and reduce abandonment caused by administrative delays (Surescripts, 2023). However, fragmented systems and out-of-workflow tools blunt the potential impact. Connected, EHR-native workflows deliver the most significant operational relief.
Current solutions include ePA platforms (automate prior authorization), hub service providers (manage enrollments after prescribing), and consumer coupon marketplaces (reduce cash price), but most are not fully integrated into EHR workflows. As a result, the care team still manages multiple systems and remains responsible for closing the loop on every prescription (Surescripts, 2023).
Make the true cost of abandonment visible by tracking callbacks, rescripts, staff hours, and added FTEs. Push for platforms that embed affordability discovery, PA, enrollment, and activation directly into the EHR workflow. Evaluate solutions based on measurable reduction in care-team workload and actual therapy starts—operational dividends, not just better patient-facing metrics.
Primary sources include annual studies from IQVIA, reports from the American Hospital Association (AHA), MGMA surveys on organizational staffing, and Surescripts’ National Progress Reports. Peer-reviewed research in Health Affairs and JAMA Internal Medicine offers granular data on EHR and PA time. These are reliable starting points for understanding the full scope of the challenge.